IDH1 and central nervous system cancer: By following the latest cIMPACT-NOW recommendation that IDH-mutant gliomas harboring homozygous CDKN2A/B deletion are equivalent to IDH1-wildtype [34], we not only confirmed this finding in the TCGA-LGG dataset but, more importantly, observed the role of TP53 status in patient survival (Figure 5A,B).